TherapeuticsMD Inc (NASDAQ:TXMD) – Investment analysts at Jefferies Group reduced their FY2020 earnings per share (EPS) estimates for shares of TherapeuticsMD in a note issued to investors on Tuesday. Jefferies Group analyst M. Andrews now expects that the company will earn $0.29 per share for the year, down from their prior forecast of $0.34.
Several other equities research analysts also recently issued reports on the stock. BidaskClub upgraded shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research note on Friday, February 9th. Oppenheimer reissued a “buy” rating and issued a $10.00 price target on shares of TherapeuticsMD in a report on Sunday, January 28th. Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Saturday, January 20th. Cantor Fitzgerald restated a “buy” rating and set a $28.00 price objective on shares of TherapeuticsMD in a report on Sunday, January 7th. Finally, Noble Financial reaffirmed a “buy” rating on shares of TherapeuticsMD in a research report on Friday, December 29th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. TherapeuticsMD currently has a consensus rating of “Buy” and a consensus target price of $14.50.
In other news, Director Tommy G. Thompson bought 5,000 shares of the business’s stock in a transaction that occurred on Friday, December 8th. The stock was acquired at an average cost of $6.21 per share, for a total transaction of $31,050.00. Following the completion of the purchase, the director now owns 3,555 shares of the company’s stock, valued at approximately $22,076.55. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 23.92% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of TXMD. Candriam Luxembourg S.C.A. lifted its stake in TherapeuticsMD by 10.4% during the third quarter. Candriam Luxembourg S.C.A. now owns 530,000 shares of the company’s stock worth $2,804,000 after purchasing an additional 50,000 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in TherapeuticsMD by 10.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock valued at $3,659,000 after buying an additional 67,855 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its position in TherapeuticsMD by 26.6% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 142,930 shares of the company’s stock valued at $756,000 after acquiring an additional 30,030 shares during the period. Swiss National Bank grew its position in TherapeuticsMD by 12.3% in the third quarter. Swiss National Bank now owns 289,800 shares of the company’s stock valued at $1,533,000 after acquiring an additional 31,800 shares during the period. Finally, State Street Corp raised its stake in TherapeuticsMD by 14.9% during the second quarter. State Street Corp now owns 4,486,585 shares of the company’s stock worth $23,647,000 after acquiring an additional 583,094 shares in the last quarter. 72.65% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/14/jefferies-group-weighs-in-on-therapeuticsmd-incs-fy2020-earnings-txmd.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.